Incidence of Primary Aldosteronism in Patients with Hypokalemia (IPAHK+): Study Design and Baseline Characteristics

Horm Metab Res 2021; 53: 787-793 DOI: 10.1055/a-1685-0583Hypokalemia plays a central role for case finding, course, treatment decision,
and prognosis of patients with primary aldosteronism. However, to date there is
a lack of high-level evidence about the incidence of primary aldosteronism in
hypokalemic patients. The IPAHK+study is an epidemiological,
cross-sectional, monocentric study to provide evidence on the incidence of PA in
a hypokalemic population. The aim of the current analysis was to describe the
baseline characteristics of the first 100 patients eligible for study inclusion.
The recruitment of patients with hypokalemia (≤3 mmol/l) is
carried out continuously on a referral-basis by the central laboratory of the
University Hospital Zurich through an automated suitability testing and data
delivery system. The careful evaluation of the first 100 reported patients was
based on the available reporting system. Out of 28 140 screened patients, 222
(0.79%) were identified with a serum potassium value
of≤3 mmol/l (mean 2.89±0.02 mmol/l). Mean
potassium levels were slightly lower in non-hypertensive subjects compared to
hypertensive subjects (mean difference 0.07 mmol/l, p=0.033),
while no significant difference was found between the sexes and patients with
and without the diagnosis of primary ...

Source: Hormone and Metabolic Research - December 10, 2021 Category: Endocrinology Authors: Gruber, Sven Stasi, Evangelia Steiner, Regula Reincke, Martin Bornstein, Stefan Beuschlein, Felix Tags: Endocrine Care Source Type: research